Biologics for atopic dermatitis—dupilumab, tralokinumab, lebrikizumab, and nemolizumab—showed sustained effectiveness and consistent safety in both trials and real-world studies. Dupilumab achieved the highest long-term treatment persistence, while nemolizumab rapidly reduced itch. Ocular surface disease was more frequent in practice but remained manageable. Biologics improved type 2 inflammation, skin barrier function, and comorbid asthma. Dose interval extension maintained disease control in most patients. The review, led by Marjolein S. de Bruin-Weller, MD (University Medical Center Utrecht), emphasized the chronic, relapsing nature of atopic dermatitis and highlighted the need for durable treatment strategies.

Source: Allergy